Skip to main content
. 2020 Nov 21;16(1):14–22. doi: 10.1515/med-2021-0002

Table 4.

Subgroup analysis for the presence or absence of rifampicin in the LTBI group

Rifampicin (n = 37) No-rifampicin (n = 31) P
AST, n (%)
≤1.5 Upper limit of normal 4 (10.8) 5 (16.1) 0.722
≤2.0 Upper limit of normal 1 (2.7) 1 (3.2) 1.0
>2.0 Upper limit of normal 2 (5.4) 0 (0) 0.496
ALT, n (%)
≤1.5 Upper limit of normal 1 (2.7) 0 (0) >0.99
≤2.0 Upper limit of normal 1 (2.7) 6 (19.4) 0.041
>2.0 Upper limit of normal 8 (21.6) 1 (3.2) 0.033
eGFR, n (%)
≤60 mL/min 2 (5.4) 1 (3.2) >0.99
≤30 mL/min 0 (0) 0 (0) >0.99
≤15 mL/min 0 (0) 0 (0) >0.99
Therapeutic regimen for BD, n (%)
Glucocorticoids 17 (45.9) 11 (35.5) 0.462
Immunosuppressants 37 (100) 31 (100)
Biological agents 4 (10.8) 6 (19.4) 0.494
Incomplete rifampicin treatment 5 (13.5) 0 (0) >0.99

BD, Behçet’s disease; LTBI, latent tuberculosis infection; CNS, central nervous system; AST, aspartate transaminase; ALT, alanine transaminase; eGFR, estimated glomerular filtration rate. P < 0.05 was considered statistically significant were shown in bold.